Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • Ruxolitinib compared with best...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Ruxolitinib compared with best available therapy for essential thrombocythaemia patients resistant or intolerant to hydroxycarbamide in majic: an investigator lead randomized trial

Ruxolitinib compared with best available therapy for essential thrombocythaemia patients resistant or intolerant to hydroxycarbamide in majic: an investigator lead randomized trial

Bibliographic Details
Main Authors: Harrison, C, Mead, A, Panchal, A, Fox, S, Yap, C, Houlton, A, Aliman, S, Wood, M, Chen, F, Coppell, J, Panoskaltsis, N, Scherber, R, Geyer, H, Dueck, A, Mesa, R, McMullin, M
Format: Conference item
Published: Ferrata Storti Foundation 2016
  • Holdings
  • Description
  • Similar Items
  • Staff View

Similar Items

  • Ruxolitinib versus best available therapy for ET intolerant or resistant to hydroxycarbamide in a randomized trial
    by: Harrison, C, et al.
    Published: (2017)
  • Correlation between treatment outcomes, baseline characteristics and molecular responses in the Majic study which compared Ruxolitinib to best available therapy in essential thrombocythemia
    by: Harrison, C, et al.
    Published: (2016)
  • Longitudinal mutational analysis in hydroxycarbamide-resistant/intolerant essential thrombocythemia treated on the majic-ET study
    by: O'Sullivan, J, et al.
    Published: (2018)
  • The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib
    by: O'Sullivan, JM, et al.
    Published: (2019)
  • Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial
    by: Harrison, CN, et al.
    Published: (2023)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs